Novo Nordisk reported DKK594.94B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Bausch Health Companies USD 25.48B 690M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Novo Nordisk DKK 90.92B 468.3B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026